NATCO Pharma Limited

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUNPHARMA.NS has a market cap of 4T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUNPHARMA.NS trades at ₹1,654.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUNPHARMA.NS's P/E ratio is 36.37. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUNPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUNPHARMA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUNPHARMA.BO has a market cap of 4T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUNPHARMA.BO trades at ₹1,654.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUNPHARMA.BO's P/E ratio is 36.37. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUNPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while DIVISLAB.BO trades at ₹6,119.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas DIVISLAB.BO's P/E ratio is 65.03. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DIVISLAB.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while DIVISLAB.NS trades at ₹6,116.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas DIVISLAB.NS's P/E ratio is 65.40. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DIVISLAB.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while TORNTPHARM.BO trades at ₹4,157.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas TORNTPHARM.BO's P/E ratio is 65.73. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check TORNTPHARM.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while TORNTPHARM.NS trades at ₹4,155.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas TORNTPHARM.NS's P/E ratio is 60.77. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check TORNTPHARM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while LUPIN.NS trades at ₹2,333.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas LUPIN.NS's P/E ratio is 23.02. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LUPIN.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while LUPIN.BO trades at ₹2,332.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas LUPIN.BO's P/E ratio is 24.72. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LUPIN.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while DRREDDY.NS trades at ₹1,232.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas DRREDDY.NS's P/E ratio is 18.16. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DRREDDY.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while DRREDDY.BO trades at ₹1,232.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas DRREDDY.BO's P/E ratio is 18.16. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DRREDDY.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ZYDUSLIFE.BO has a market cap of 921.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ZYDUSLIFE.BO trades at ₹915.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ZYDUSLIFE.BO's P/E ratio is 18.67. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ZYDUSLIFE.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ZYDUSLIFE.NS has a market cap of 921.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ZYDUSLIFE.NS trades at ₹915.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ZYDUSLIFE.NS's P/E ratio is 18.67. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ZYDUSLIFE.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, MANKIND.NS has a market cap of 858.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while MANKIND.NS trades at ₹2,079.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas MANKIND.NS's P/E ratio is 48.26. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MANKIND.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, MANKIND.BO has a market cap of 858.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while MANKIND.BO trades at ₹2,078.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas MANKIND.BO's P/E ratio is 47.96. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MANKIND.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AUROPHARMA.BO has a market cap of 784.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AUROPHARMA.BO trades at ₹1,350.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AUROPHARMA.BO's P/E ratio is 22.92. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AUROPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AUROPHARMA.NS has a market cap of 783.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AUROPHARMA.NS trades at ₹1,349.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AUROPHARMA.NS's P/E ratio is 22.47. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AUROPHARMA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ALKEM.BO has a market cap of 650.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ALKEM.BO trades at ₹5,440.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ALKEM.BO's P/E ratio is 27.43. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALKEM.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ALKEM.NS has a market cap of 650.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ALKEM.NS trades at ₹5,440.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ALKEM.NS's P/E ratio is 27.46. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALKEM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GLENMARK.NS has a market cap of 610.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GLENMARK.NS trades at ₹2,163.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GLENMARK.NS's P/E ratio is 57.41. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLENMARK.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GLENMARK.BO has a market cap of 610.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GLENMARK.BO trades at ₹2,162.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GLENMARK.BO's P/E ratio is 57.31. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLENMARK.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, LAURUSLABS.NS has a market cap of 593B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while LAURUSLABS.NS trades at ₹1,098.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas LAURUSLABS.NS's P/E ratio is 70.14. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LAURUSLABS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, LAURUSLABS.BO has a market cap of 592.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while LAURUSLABS.BO trades at ₹1,097.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas LAURUSLABS.BO's P/E ratio is 70.70. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LAURUSLABS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVENPHAR.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVENPHAR.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, IPCALAB.NS has a market cap of 369.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while IPCALAB.NS trades at ₹1,456.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas IPCALAB.NS's P/E ratio is 40.63. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IPCALAB.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, IPCALAB.BO has a market cap of 369.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while IPCALAB.BO trades at ₹1,456.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas IPCALAB.BO's P/E ratio is 40.62. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IPCALAB.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AJANTPHARM.NS has a market cap of 350.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AJANTPHARM.NS trades at ₹2,806.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AJANTPHARM.NS's P/E ratio is 34.53. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AJANTPHARM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AJANTPHARM.BO has a market cap of 350.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AJANTPHARM.BO trades at ₹2,803.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AJANTPHARM.BO's P/E ratio is 34.56. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AJANTPHARM.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, JBCHEPHARM.NS has a market cap of 322B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while JBCHEPHARM.NS trades at ₹2,005.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas JBCHEPHARM.NS's P/E ratio is 42.24. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JBCHEPHARM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, JBCHEPHARM.BO has a market cap of 321.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while JBCHEPHARM.BO trades at ₹2,003.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas JBCHEPHARM.BO's P/E ratio is 42.19. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JBCHEPHARM.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, EMCURE.NS has a market cap of 303.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while EMCURE.NS trades at ₹1,600.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas EMCURE.NS's P/E ratio is 34.89. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check EMCURE.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PEL.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, WOCKPHARMA.BO has a market cap of 218.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while WOCKPHARMA.BO trades at ₹1,344.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas WOCKPHARMA.BO's P/E ratio is 1110.79. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check WOCKPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, WOCKPHARMA.NS has a market cap of 218.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while WOCKPHARMA.NS trades at ₹1,343.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas WOCKPHARMA.NS's P/E ratio is 1092.52. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check WOCKPHARMA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ASTRAZEN.NS has a market cap of 207.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ASTRAZEN.NS trades at ₹8,299.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ASTRAZEN.NS's P/E ratio is 103.41. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ASTRAZEN.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ASTRAZEN.BO has a market cap of 207.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ASTRAZEN.BO trades at ₹8,291.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ASTRAZEN.BO's P/E ratio is 103.53. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ASTRAZEN.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, NATCOPHARM.NS has a market cap of 197.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while NATCOPHARM.NS trades at ₹1,104.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas NATCOPHARM.NS's P/E ratio is 12.70. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO and NATCOPHARM.NS have similar daily volatility (3.12).Check NATCOPHARM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, PPLPHARMA.BO has a market cap of 193.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while PPLPHARMA.BO trades at ₹146.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas PPLPHARMA.BO's P/E ratio is -115.04. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PPLPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, NEULANDLAB.NS has a market cap of 191.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while NEULANDLAB.NS trades at ₹14,951.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas NEULANDLAB.NS's P/E ratio is 107.45. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NEULANDLAB.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, NEULANDLAB.BO has a market cap of 191.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while NEULANDLAB.BO trades at ₹14,948.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas NEULANDLAB.BO's P/E ratio is 107.47. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NEULANDLAB.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ERIS.NS has a market cap of 190B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ERIS.NS trades at ₹1,371.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ERIS.NS's P/E ratio is 43.54. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ERIS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ERIS.BO has a market cap of 189.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ERIS.BO trades at ₹1,370.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ERIS.BO's P/E ratio is 43.38. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ERIS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GRANULES.NS has a market cap of 153.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GRANULES.NS trades at ₹631.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GRANULES.NS's P/E ratio is 28.11. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GRANULES.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GRANULES.BO has a market cap of 153.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GRANULES.BO trades at ₹631.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GRANULES.BO's P/E ratio is 28.10. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GRANULES.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, COHANCE.BO has a market cap of 144.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while COHANCE.BO trades at ₹378.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas COHANCE.BO's P/E ratio is 74.88. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check COHANCE.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, COHANCE.NS has a market cap of 144.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while COHANCE.NS trades at ₹377.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas COHANCE.NS's P/E ratio is 74.83. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check COHANCE.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, APLLTD.NS has a market cap of 142.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while APLLTD.NS trades at ₹724.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas APLLTD.NS's P/E ratio is 22.80. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check APLLTD.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, APLLTD.BO has a market cap of 142.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while APLLTD.BO trades at ₹723.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas APLLTD.BO's P/E ratio is 22.90. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check APLLTD.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, JUBLPHARMA.BO has a market cap of 141.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while JUBLPHARMA.BO trades at ₹891.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas JUBLPHARMA.BO's P/E ratio is 32.76. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JUBLPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, JUBLPHARMA.NS has a market cap of 141.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while JUBLPHARMA.NS trades at ₹890.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas JUBLPHARMA.NS's P/E ratio is 32.74. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JUBLPHARMA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, CAPLIPOINT.BO has a market cap of 129.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while CAPLIPOINT.BO trades at ₹1,708.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas CAPLIPOINT.BO's P/E ratio is 21.22. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPLIPOINT.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, CAPLIPOINT.NS has a market cap of 129.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while CAPLIPOINT.NS trades at ₹1,708.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas CAPLIPOINT.NS's P/E ratio is 21.22. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPLIPOINT.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ALIVUS.NS has a market cap of 128.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ALIVUS.NS trades at ₹1,046.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ALIVUS.NS's P/E ratio is 23.67. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALIVUS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ALIVUS.BO has a market cap of 128B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ALIVUS.BO trades at ₹1,043.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ALIVUS.BO's P/E ratio is 23.70. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALIVUS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPPL.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, STAR.BO has a market cap of 92.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while STAR.BO trades at ₹1,000.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas STAR.BO's P/E ratio is 18.54. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check STAR.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, STAR.NS has a market cap of 92.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while STAR.NS trades at ₹1,000.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas STAR.NS's P/E ratio is 18.03. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check STAR.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, VIYASH.NS has a market cap of 91.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while VIYASH.NS trades at ₹208.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas VIYASH.NS's P/E ratio is 80.60. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check VIYASH.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SHILPAMED.NS has a market cap of 82.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SHILPAMED.NS trades at ₹420.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SHILPAMED.NS's P/E ratio is 37.14. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SHILPAMED.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, PGHL.BO has a market cap of 82.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while PGHL.BO trades at ₹4,943.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas PGHL.BO's P/E ratio is 34.72. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PGHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PGHL.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, PGHL.NS has a market cap of 82.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while PGHL.NS trades at ₹4,943.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas PGHL.NS's P/E ratio is 34.63. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PGHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PGHL.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AKUMS.NS has a market cap of 79B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AKUMS.NS trades at ₹515.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AKUMS.NS's P/E ratio is 24.69. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AKUMS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUDEEPPHRM.NS has a market cap of 68.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUDEEPPHRM.NS trades at ₹609.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUDEEPPHRM.NS's P/E ratio is 40.93. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUDEEPPHRM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AARTIPHARM.NS has a market cap of 62.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AARTIPHARM.NS trades at ₹689.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AARTIPHARM.NS's P/E ratio is 29.25. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIPHARM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AARTIPHARM.BO has a market cap of 62.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AARTIPHARM.BO trades at ₹689.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AARTIPHARM.BO's P/E ratio is 29.47. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIPHARM.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, FDC.BO has a market cap of 57.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while FDC.BO trades at ₹351.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas FDC.BO's P/E ratio is 26.49. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check FDC.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, FDC.NS has a market cap of 57.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while FDC.NS trades at ₹351.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas FDC.NS's P/E ratio is 26.39. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check FDC.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SEQUENT.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SEQUENT.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SPARC.NS has a market cap of 48.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SPARC.NS trades at ₹148.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SPARC.NS's P/E ratio is -17.98. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SPARC.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SPARC.BO has a market cap of 48.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SPARC.BO trades at ₹148.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SPARC.BO's P/E ratio is -17.96. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SPARC.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUVEN.NS has a market cap of 45.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUVEN.NS trades at ₹195.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUVEN.NS's P/E ratio is -15.87. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVEN.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SUVEN.BO has a market cap of 45.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SUVEN.BO trades at ₹194.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SUVEN.BO's P/E ratio is -15.81. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVEN.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SHILPAMED.BO has a market cap of 41.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SHILPAMED.BO trades at ₹419.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SHILPAMED.BO's P/E ratio is 37.09. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SHILPAMED.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, INNOVACAP.NS has a market cap of 39.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while INNOVACAP.NS trades at ₹689.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas INNOVACAP.NS's P/E ratio is 29.76. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check INNOVACAP.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AARTIDRUGS.NS has a market cap of 32.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AARTIDRUGS.NS trades at ₹355.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AARTIDRUGS.NS's P/E ratio is 16.07. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIDRUGS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, AARTIDRUGS.BO has a market cap of 32.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while AARTIDRUGS.BO trades at ₹354.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas AARTIDRUGS.BO's P/E ratio is 16.04. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIDRUGS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, RPGLIFE.BO has a market cap of 31.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while RPGLIFE.BO trades at ₹1,893.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas RPGLIFE.BO's P/E ratio is 15.45. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check RPGLIFE.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GUJTHEM.NS has a market cap of 31.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GUJTHEM.NS trades at ₹285.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GUJTHEM.NS's P/E ratio is 64.93. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUJTHEM.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, RPGLIFE.NS has a market cap of 31.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while RPGLIFE.NS trades at ₹1,881.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas RPGLIFE.NS's P/E ratio is 15.36. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check RPGLIFE.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GUFICBIO.NS has a market cap of 30.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GUFICBIO.NS trades at ₹302.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GUFICBIO.NS's P/E ratio is 60.69. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUFICBIO.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, GUFICBIO.BO has a market cap of 30.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while GUFICBIO.BO trades at ₹301.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas GUFICBIO.BO's P/E ratio is 60.36. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUFICBIO.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ORCHPHARMA.NS has a market cap of 28.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ORCHPHARMA.NS trades at ₹562.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ORCHPHARMA.NS's P/E ratio is 150.27. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ORCHPHARMA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ORCHPHARMA.BO has a market cap of 28.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ORCHPHARMA.BO trades at ₹559.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ORCHPHARMA.BO's P/E ratio is 149.12. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ORCHPHARMA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, BLISSGVS.NS has a market cap of 27.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while BLISSGVS.NS trades at ₹258.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas BLISSGVS.NS's P/E ratio is 25.46. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check BLISSGVS.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, BLISSGVS.BO has a market cap of 27.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while BLISSGVS.BO trades at ₹258.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas BLISSGVS.BO's P/E ratio is 25.43. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check BLISSGVS.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, NOVARTIND.BO has a market cap of 24.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while NOVARTIND.BO trades at ₹1,000.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas NOVARTIND.BO's P/E ratio is 25.43. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NOVARTIND.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, IOLCP.BO has a market cap of 24.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while IOLCP.BO trades at ₹82.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas IOLCP.BO's P/E ratio is 20.79. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IOLCP.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, IOLCP.NS has a market cap of 24.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while IOLCP.NS trades at ₹82.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas IOLCP.NS's P/E ratio is 20.79. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IOLCP.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, UNICHEMLAB.BO has a market cap of 23.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while UNICHEMLAB.BO trades at ₹339.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas UNICHEMLAB.BO's P/E ratio is 8.12. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check UNICHEMLAB.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, UNICHEMLAB.NS has a market cap of 23.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while UNICHEMLAB.NS trades at ₹335.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas UNICHEMLAB.NS's P/E ratio is 7.66. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check UNICHEMLAB.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SOLARA.NS has a market cap of 23.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SOLARA.NS trades at ₹485.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SOLARA.NS's P/E ratio is -100.58. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SOLARA.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, SOLARA.BO has a market cap of 23.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while SOLARA.BO trades at ₹485.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas SOLARA.BO's P/E ratio is -100.99. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SOLARA.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, HIKAL.NS has a market cap of 22.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while HIKAL.NS trades at ₹179.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas HIKAL.NS's P/E ratio is -168.14. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check HIKAL.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, HIKAL.BO has a market cap of 22.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while HIKAL.BO trades at ₹179.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas HIKAL.BO's P/E ratio is 224.31. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check HIKAL.BO's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, ALEMBICLTD.NS has a market cap of 22.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while ALEMBICLTD.NS trades at ₹86.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas ALEMBICLTD.NS's P/E ratio is 6.93. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALEMBICLTD.NS's competition here

NATCOPHARM.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 197.7B. In comparison, MOREPENLAB.BO has a market cap of 22B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹1,103.90, while MOREPENLAB.BO trades at ₹40.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 12.85, whereas MOREPENLAB.BO's P/E ratio is 22.45. In terms of profitability, NATCOPHARM.BO's ROE is +0.20%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to MOREPENLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MOREPENLAB.BO's competition here